GlassScriptPhysician profile
Shari Orr
NPI 1689191975
$1,556.95
in general payments reported to CMS, 2019-2025
13 companies · $310 in 2025
The $310 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $998 · 2024: $249 · 2025: $310.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,557.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,556.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $241.78 | 2023 | |
| Alexion Pharmaceuticals, INC. | $211.58 | 2023-2024 | Ultomiris |
| Cordis US Corp. | $164.83 | 2023 | S.M.A.R.T. |
| Alk-Abello, INC | $144.24 | 2025 | Odactra |
| Medtronic, INC. | $135.21 | 2023 | Interstim |
| Amgen INC. | $125.00 | 2023 | Repatha |
| Sage Therapeutics, LLC | $120.00 | 2023 | |
| Madrigal Pharmaceuticals | $107.19 | 2025 | Rezdiffra |
| Abiomed | $105.26 | 2024 | Impella |
| Sumitomo Pharma America, INC. | $72.26 | 2023 | Gemtesa |
| Boston Scientific Corporation | $58.87 | 2025 | Watchman Flx |
| Veryan Medical Incorporated | $48.69 | 2023 | Biomimics 3d Vascular Stent System |
| Eisai INC. | $22.04 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shari Orr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.